Hairy cell leukemia (HCL) is predominantly seen in men with a median age of 52, and often treated with 2-chlorodeoxyadenosine (cladribine, 2-CdA). Perhaps as a result of the demographics of HCL, studies of ovarian function after such therapy are lacking, even though cladribine can induce DNA strand breaks. In this report, the first case of a patient diagnosed with HCL who then went on to a successful pregnancy is described, suggesting that fertility may be preserved in at least some female patients treated with this agent.
No takes yet. Share an insight, caveat, or question.
Robert Z. Orlowski (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: